Jim Cramer on Arcus Biosciences: "Let This Be Your Speculation"

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the stocks Jim Cramer shed light on. When a caller asked about the company during the lightning round, Cramer said:

“I’m of two minds here. Here’s the problem. One is, is that they’re losing a lot of money. But second, there’s room for one speculation in everybody’s portfolio. Let this be your speculation. But if you do this, you have to promise me that the other stocks are not going to be speculative because it’s too risky to just bank it all on Arcus. Too risky.”

Arcus Biosciences, Inc. (NYSE:RCUS) is a clinical-stage biopharmaceutical company developing cancer therapies, including antibodies and small-molecule inhibitors targeting various tumor pathways. The company’s pipeline addresses multiple cancers, such as lung, kidney, pancreatic, and colorectal. On August 6, Arcus Biosciences, Inc. (NYSE:RCUS) reported revenue of $160 million, which was up over 310% year-over-year. The company closed the June quarter with cash, cash equivalents, and marketable securities of $927 million compared to $992 million at the end of the December 2024 quarter.

While we acknowledge the potential of RCUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.